Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Global Viral Vector Manufacturing Research Report 2018 | ||
By: PR Newswire Association LLC. - 22 Oct 2018 | Back to overview list |
|
DUBLIN, Oct. 22, 2018 /PRNewswire/ -- The "Global Viral Vector Manufacturing Markets and Technologies Through 2022" report has been added to ResearchAndMarkets.com's offering. The report provides an analysis based on each market segment, which includes by type, disease and application. The global viral vector vaccine manufacturing market by type is further segmented on the basis of adenoviral vectors, retroviral vectors, lentiviral vectors, adeno-associated viral vectors, cytomegalovirus, pox virus and other viral vectors. Rising prevalence of human chronic diseases and veterinary diseases across the globe is propelling the adoption of viral vector vaccines because vaccines are recognized to be the most cost-effective and efficient medium. According to World Health Organization (WHO), the number of patients suffering from chronic diseases such as cancer, chronic respiratory diseases, cardiovascular diseases and others was noted at about 130 million people in 2005 and is expected to reach around 173 million by 2030. Moreover, according to the WHO World Health Statistics report, cardiovascular disease, cancer and chronic respiratory disease caused around 17.9 million, 9 million and 3.8 million, respectively, which in total accounts for 75% of noncommunicable disease deaths across the globe. In addition, according to Avert Organization (U.K.), in 2016, approximately 36.7 million people were found to be suffering from human immunodeficiency virus (HIV), and 1 million people died due to HIV-related diseases in 2016. Furthermore, according to the report, in 2016, 5.1 million new cases of acquired immune deficiency syndrome (AIDS) were registered in Asia-Pacific, compared with 0.23 million in North Africa and the Middle East. Moreover, Sub-Saharan Africa registered the highest prevalence of AIDS, with more than 19 million infected by HIV in 2016. Viral-vector-based vaccines have the ability to enrich immunogenicity without an adjuvant and induce a vigorous cytotoxic T lymphocyte (CTL) response to abolish virus-infected cells. For instance, Royal Free Hospital (U.K.) and Oxford University Hospital (U.K.), in 2017, were involved in Phase I clinical trial of the adeno-associated viral vector (FLT180a) in patients with hemophilia B. Moreover, in 2017, the Orthopaedic Hemophilia Treatment Center (California), Medical University of South Carolina (MUSC), (South Carolina), Gulf States Hemophilia and Thrombophilia Center (Texas) were involved in a Phase II trial of BAX 888 drug, an adeno-associated virus serotype 8 (AAV8) vector expressing B-domain-deleted factor VIII (BDD-FVIII) in severe hemophilia A subjects administered a single intravenous infusion. Key Topics Covered: Chapter 1 Introduction
Chapter 2 Summary and Highlights
Chapter 4 Market Drivers
Chapter 5 Market Breakdown by Type
Chapter 6 Market Breakdown by Disease Application
Chapter 7 Market Breakdown by Application Type
Chapter 8 Market Breakdown by Region
Chapter 9 Viral Vector Manufacturing Industry Structure
Chapter 10 Patent Analysis
Chapter 11 Company Profiles
For more information about this report visit https://www.researchandmarkets.com/research/zwjkbl/global_viral?w=5 Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager. Media Contact: Research and Markets View original content:http://www.prnewswire.com/news-releases/global-viral-vector-manufacturing-research-report-2018-300735332.html SOURCE Research and Markets |
||
|
||
Copyright 2018 PR Newswire Association LLC. | Back to overview list |